Pretreatment of human AML cells with neutralizing CXCR4 antibodies blocked their homing to the BM and spleen of NOD/SCID/β2Mnull mice and treating mice previously engrafted with AML cells with antibodies against CXCR4 resulted in a dramatic decrease in leukaemia cell levels in a dose‐ and time‐dependent manner.36 Here, CXCR4 is linked to acute myeloid leukemia.